# Cullinan Therapeutics, Inc.: financial statements, quarterly

CGEM · Nasdaq · CIK 1789972 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cgem.md) · [Financials](/companies/cgem/financials.md) · [Filings](/companies/cgem/filings.md) · [Insiders](/companies/cgem/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cgem/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [33.8](/filings/0000950170-24-122795.md) | [34.8 d](/filings/0000950170-25-028346.md) | [30.6](/filings/0000950170-25-066384.md) | [36.3](/filings/0000950170-25-104551.md) | [35.5](/filings/0001193125-25-268066.md) | [40.5 d](/filings/0001193125-26-099362.md) | [41.5](/filings/0001193125-26-210304.md) | [61.0](/filings/0001193125-26-336717.md) | [42.0](/filings/0001193125-25-268066.md) | [42.9 d](/filings/0001193125-26-099362.md) | [42.1](/filings/0001193125-26-210304.md) | [44.4](/filings/0001193125-26-336717.md) |
| Operating income | $m | [(45.2)](/filings/0000950170-24-122795.md) | [(45.5) d](/filings/0000950170-25-028346.md) | [(43.0)](/filings/0000950170-25-066384.md) | [(50.0)](/filings/0000950170-25-104551.md) | [(48.9)](/filings/0001193125-25-268066.md) | [(55.0) d](/filings/0001193125-26-099362.md) | [(55.0)](/filings/0001193125-26-210304.md) | [(75.8)](/filings/0001193125-26-336717.md) | [(55.6)](/filings/0001193125-25-268066.md) | [(55.3) d](/filings/0001193125-26-099362.md) | [(53.7)](/filings/0001193125-26-210304.md) | [(57.3)](/filings/0001193125-26-336717.md) |
| Income tax | $m | [0.0](/filings/0000950170-23-060679.md) | [(14.1) d](/filings/0000950170-25-028346.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(39.2)](/filings/0000950170-24-122795.md) | [(23.8) d](/filings/0000950170-25-028346.md) | [(37.1)](/filings/0000950170-25-066384.md) | [(42.0)](/filings/0000950170-25-104551.md) | [(40.6)](/filings/0001193125-25-268066.md) | [(47.6) d](/filings/0001193125-26-099362.md) | [(48.5)](/filings/0000950170-25-066384.md) | [(70.1)](/filings/0000950170-25-104551.md) | [(50.6)](/filings/0001193125-25-268066.md) | [(50.7) d](/filings/0001193125-26-099362.md) | [(49.7)](/filings/0001193125-26-336717.md) | [(53.7)](/filings/0001193125-26-336717.md) |
| Diluted EPS | $ per share | [(0.91)](/filings/0000950170-24-122795.md) | not reported | [(0.86)](/filings/0000950170-24-060535.md) | [(0.75)](/filings/0000950170-24-093320.md) | [(0.69)](/filings/0000950170-24-122795.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.91)](/filings/0000950170-24-122795.md) | not reported | [(0.86)](/filings/0000950170-24-060535.md) | [(0.75)](/filings/0000950170-24-093320.md) | [(0.69)](/filings/0000950170-24-122795.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.8](/filings/0000950170-23-060679.md) | [98.4](/filings/0000950170-25-028346.md) | [74.2](/filings/0000950170-24-060535.md) | [115](/filings/0000950170-24-093320.md) | [102](/filings/0000950170-24-122795.md) | [83.0](/filings/0001193125-26-099362.md) | [76.7](/filings/0000950170-25-066384.md) | [72.8](/filings/0000950170-25-104551.md) | [103](/filings/0001193125-25-268066.md) | [88.3](/filings/0001193125-26-336717.md) | [75.1](/filings/0001193125-26-210304.md) | [78.6](/filings/0001193125-26-336717.md) |
| Current assets | $m | [477](/filings/0000950170-23-060679.md) | [480](/filings/0000950170-25-028346.md) | [446](/filings/0000950170-24-060535.md) | [678](/filings/0000950170-24-093320.md) | [592](/filings/0000950170-24-122795.md) | [415](/filings/0001193125-26-099362.md) | [318](/filings/0000950170-25-066384.md) | [276](/filings/0000950170-25-104551.md) | [342](/filings/0001193125-25-268066.md) | [387](/filings/0001193125-26-336717.md) | [361](/filings/0001193125-26-210304.md) | [342](/filings/0001193125-26-336717.md) |
| Total assets | $m | [495](/filings/0000950170-23-060679.md) | [484](/filings/0000950170-25-028346.md) | [449](/filings/0000950170-24-060535.md) | [681](/filings/0000950170-24-093320.md) | [653](/filings/0000950170-24-122795.md) | [622](/filings/0001193125-26-099362.md) | [580](/filings/0000950170-25-066384.md) | [520](/filings/0000950170-25-104551.md) | [484](/filings/0001193125-25-268066.md) | [448](/filings/0001193125-26-336717.md) | [403](/filings/0001193125-26-210304.md) | [364](/filings/0001193125-26-336717.md) |
| Current liabilities | $m | [23.4](/filings/0000950170-23-060679.md) | [28.1](/filings/0000950170-25-028346.md) | [21.9](/filings/0000950170-24-060535.md) | [23.5](/filings/0000950170-24-093320.md) | [24.2](/filings/0000950170-24-122795.md) | [30.6](/filings/0001193125-26-099362.md) | [27.3](/filings/0000950170-25-066384.md) | [28.1](/filings/0000950170-25-104551.md) | [32.8](/filings/0001193125-25-268066.md) | [37.7](/filings/0001193125-26-336717.md) | [35.2](/filings/0001193125-26-210304.md) | [40.6](/filings/0001193125-26-336717.md) |
| Total liabilities | $m | [25.9](/filings/0000950170-23-060679.md) | [30.3](/filings/0000950170-25-028346.md) | [23.8](/filings/0000950170-24-060535.md) | [25.0](/filings/0000950170-24-093320.md) | [25.4](/filings/0000950170-24-122795.md) | [31.5](/filings/0001193125-26-099362.md) | [27.8](/filings/0000950170-25-066384.md) | [28.2](/filings/0000950170-25-104551.md) | [32.8](/filings/0001193125-25-268066.md) | [39.6](/filings/0001193125-26-336717.md) | [36.8](/filings/0001193125-26-210304.md) | [42.0](/filings/0001193125-26-336717.md) |
| Shareholders' equity | $m | [469](/filings/0000950170-23-060679.md) | [454](/filings/0000950170-25-028346.md) | [426](/filings/0000950170-24-060535.md) | [656](/filings/0000950170-24-093320.md) | [628](/filings/0000950170-24-122795.md) | [590](/filings/0001193125-26-099362.md) | [552](/filings/0000950170-25-066384.md) | [492](/filings/0000950170-25-104551.md) | [451](/filings/0001193125-25-268066.md) | [409](/filings/0001193125-26-099362.md) | [366](/filings/0001193125-26-336717.md) | [322](/filings/0001193125-26-336717.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(34.1) d](/filings/0000950170-24-122795.md) | [(18.1) d](/filings/0000950170-25-028346.md) | [(38.2)](/filings/0000950170-25-066384.md) | [(36.3) d](/filings/0000950170-25-104551.md) | [(34.1) d](/filings/0001193125-25-268066.md) | [(36.6) d](/filings/0001193125-26-099362.md) | [(43.2)](/filings/0001193125-26-210304.md) | [(57.6) d](/filings/0001193125-26-336717.md) | [(36.9) d](/filings/0001193125-25-268066.md) | [(38.1) d](/filings/0001193125-26-099362.md) | [(46.0)](/filings/0001193125-26-210304.md) | [(38.2) d](/filings/0001193125-26-336717.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122795.md) | [0.0 d](/filings/0000950170-25-028346.md) | [0.0](/filings/0000950170-24-060535.md) | [0.0 d](/filings/0000950170-24-093320.md) | [0.0 d](/filings/0001193125-25-268066.md) | [0.0 d](/filings/0001193125-26-099362.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-099362.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.3](/filings/0000950170-22-016258.md) | [43.4](/filings/0000950170-22-024683.md) | [44.4](/filings/0000950170-23-021253.md) | [46.4](/filings/0000950170-23-040964.md) | [45.6](/filings/0000950170-23-060679.md) | [40.7](/filings/0000950170-24-060535.md) | [40.0](/filings/0000950170-24-093320.md) | [42.7](/filings/0000950170-24-122795.md) | [43.0](/filings/0000950170-24-060535.md) | [55.1](/filings/0000950170-24-093320.md) | [58.3](/filings/0000950170-24-122795.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,354,694 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336717.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.